Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-05
2005-04-05
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06875762
ABSTRACT:
The present invention provides compounds of formula I:wherein R1, R2, X and Y have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods as well as processes and intermediates useful for preparing compounds of formula (I).
REFERENCES:
patent: 3676558 (1972-07-01), Hester, Jr.
patent: 3839357 (1974-10-01), Hester, Jr.
patent: 0377238 (1990-07-01), None
patent: WO-0077001 (2000-12-01), None
patent: WO-0077002 (2000-12-01), None
patent: WO-00077010 (2000-12-01), None
Baxter, G., “5-HT2 receptor subtype: a family re-united?”,Trends in Pharmacological Reviews, 16, (1995),pp. 105-110.
Bos, M., “Novel Antagonists of 5HT2C Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder”,Journal of Medicinal Chemistry, 40(17), (Aug. 15, 1997),pp. 2762-2769.
Boullin, D. J.,Serotonin in Mental Abnormalities, John Wiley & Sons, Ltd.,(1978),pp. 1-316.
Bromidge, S. M., “Novel and Selective 5-HT2C/2B Receptor Antagonists as Potential Anxiolytic Agents: Synthesis, Quantitative Structure-Activity Relationships, and Molecular Modeling of Substituted 1-(3-Pyridylcarbamoyl)indolines”,Journal of Medicinal Chemistry, 41(10), (May 7, 1998), pp. 1598-1612.
Dekeyne, A., “Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmalogical analysis”,Neuropharmacology, 38(2), (Mar. 1999),pp. 415-423.
Gershon, M. D., et al., “5-Hydroxytryptamine and enteric neurones”,The Peripheral Actions of 5-Hydroxytryptamine, Chapter 11, Oxford University Press,(1989),pp. 247-273.
Glennon, R. A., “Serotonin Receptors: Clinical Implications”,Neuroscience&Behavioral Reviews, 14(1), (1990),pp. 35-47.
Hoyer, D., “VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)”,Pharmacological Reviews, 46(2), (Jun. 1994),pp. 157-203.
Jenck, F., “The role of 5-HT2C receptors in affective disorders”,Exp. Opin. Invest. Drugs, 7(10), (1998),pp. 1587-1599.
Martin, J. R., “5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential”,The Journal of Pharmacology and Experimental Therapeutics, 286(2), (1998),pp. 913-924.
Robichaud, A J., et al., “Recent Advances in Selective Serotonin Receptor Modulation”,Annual Reports in Medicinal Chemistry, 56, (2000), 11-20.
Saxena, P. R., et al., “Cardiovascular Effects of Serotonin Agonists and Antagonists”,Journal of Cardiovascular Pharmacology, 15(Suppl. 7), (1990),pp. S17-S34.
Saxena, P R., “Seratonin Receptors: Subtypes, Functional Responses and Therapeutic Relevance”,Pharmac. Ther., 66, (1995),339-368.
Acker Brad A.
Ennis Michael D.
Frank Kristine E.
Hester Jackson B.
Jacobsen Eric Jon
Pfizer
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Tetracyclic azepinoindole compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetracyclic azepinoindole compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetracyclic azepinoindole compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374794